Waldenström's macroglobulinemia historical perspective

Waldenström's macroglobulinemia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Waldenström's macroglobulinemia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Bone Marrow Aspiration and Biopsy
Electrophoresis and Immunofixation
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Waldenström's macroglobulinemia historical perspective On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Waldenström's macroglobulinemia historical perspective All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Waldenström's macroglobulinemia historical perspective
CDC on Waldenström's macroglobulinemia historical perspective
Waldenström's macroglobulinemia historical perspective in the news
Blogs on Waldenström's macroglobulinemia historical perspective
Directions to Hospitals Treating Waldenström's macroglobulinemia
Risk calculators and risk factors for Waldenström's macroglobulinemia historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mirdula Sharma, MBBS [2]

Overview

Waldenström's macroglobulinemia was first discovered by Jan G. Waldenström, a Swedish physician in 1944.

Historical Perspective

Waldenström's macroglobulinemia was first discovered by Jan G. Waldenström, a Swedish oncologist in 1944 in two patients with bleeding from the nose and mouth, anemia, decreased levels of fibrinogen in the blood (hypofibrinogenemia), swollen lymph nodes, neoplastic plasma cells in bone marrow, and increased viscosity of the blood due to increased levels of a class of heavy proteins called macroglobulins.